Exosome-based detection of EGFR T790M in plasma and pleural fluid of prospectively enrolled non-small cell lung cancer patients after first-line tyrosine kinase inhibitor therapy

Table 2 Comparing the detection of the EGFR activating mutation between the Cobas assay, ddPCR and NGS using plasma from NSCLC patients

EGFR genotype	TP and TN^a (38 cases with NGS results)	Cobas assay using cfDNA (n = 54)		ddPCR using cfDNA + exoTNA (n = 54)		NGS using cfDNA + exoTNA (n = 38)
EGFR genotype	TP and TN^a (38 cases with NGS results)	Mutant type	Wild-type	Mutant type	Wild-type	Mutant type	Wild-type
Mutant type	43 (32)	40	3	41	2	30	2
Wild-type	11 (6)	0	11	0	11	0	6
Sensitivity,% (95% CI)		93 (91.7–94.3)		95.3 (94–96.6)		93.8 (92.2–95.4)
Specificity, % (95% CI)		100 (98.7–101)		100 (98.7–101)		100 (98.4–102)
Accuracy, % (95% CI)		94.4 (93.1–95.7)		96.3 (95–97.6)		94.7 (93.1–96.3)

^a‘True positive’ was defined as a activating mutation positive in more than two or more liquid biopsy platforms among Cobas, ddPCR, and NGS or positive in tissue genotyping and one or more liquid biopsy platforms. ‘True negative’ was defined as activating mutation negative in all tested liquid biopsy platforms
NSCLC non-small cell lung cancer, TP true positive, TN true negative, CI confidence interval

ISSN: 1475-2867